Cargando…

Serum thyroglobulin is associated with orbitopathy in Graves’ disease

PURPOSE: Serum thyroglobulin levels are often elevated in Graves’ disease (GD) and in most cases decrease during treatment. Its relation to Graves’ orbitopathy (GO) has not been clarified. Previously, a risk of GO has been linked to smoking, TSH receptor stimulation, high TSH-receptor antibodies (TR...

Descripción completa

Detalles Bibliográficos
Autores principales: Khamisi, S., Lundqvist, M., Emadi, P., Almby, K., Ljunggren, Ö., Karlsson, F. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357771/
https://www.ncbi.nlm.nih.gov/pubmed/33515213
http://dx.doi.org/10.1007/s40618-021-01505-8
_version_ 1783737204523139072
author Khamisi, S.
Lundqvist, M.
Emadi, P.
Almby, K.
Ljunggren, Ö.
Karlsson, F. A.
author_facet Khamisi, S.
Lundqvist, M.
Emadi, P.
Almby, K.
Ljunggren, Ö.
Karlsson, F. A.
author_sort Khamisi, S.
collection PubMed
description PURPOSE: Serum thyroglobulin levels are often elevated in Graves’ disease (GD) and in most cases decrease during treatment. Its relation to Graves’ orbitopathy (GO) has not been clarified. Previously, a risk of GO has been linked to smoking, TSH receptor stimulation, high TSH-receptor antibodies (TRAb), low thyroid peroxidase and thyroglobulin antibodies (TPOAb, TgAb). METHODS: We examined Tg levels in 30 consecutive patients with GD were given drug therapy (methimazole + thyroxine) for up to 24 months. GO was identified by clinical signs and symptoms. 17 patients had GO, 11 of whom had it at diagnosis while 6 developed GO during treatment. During the study, 5 subjects were referred to radioiodine treatment, 3 to surgery. The remaining 22 subjects (GO n = 12, non-GO n = 10) completed the drug regimen. RESULTS: At diagnosis, Tg levels in GO patients (n = 11) were higher (84, 30–555 µg/L, median, range) than in non-GO patients (n = 19) (38, 3.5–287 µg/L), p = 0.042. Adding the 6 subjects who developed eye symptoms during treatment to the GO group (n = 17), yielded p = 0.001 vs. non-GO (n = 13). TRAb tended to be higher, while TPOAb and TgAb tended to be lower in the GO group. For the 22 patients who completed the drug regimen, Tg levels were higher in GO (n = 12) vs. non-GO (n = 10), p = 0.004, whereas TRAb levels did not differ. CONCLUSION: The data may suggest that evaluation of thyroglobulin levels in GD could contribute to identify patients at increased risk of developing GO. Possibly, thyroidal release of Tg in GD reflects a disturbance that also impacts retroorbital tissues.
format Online
Article
Text
id pubmed-8357771
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83577712021-08-30 Serum thyroglobulin is associated with orbitopathy in Graves’ disease Khamisi, S. Lundqvist, M. Emadi, P. Almby, K. Ljunggren, Ö. Karlsson, F. A. J Endocrinol Invest Original Article PURPOSE: Serum thyroglobulin levels are often elevated in Graves’ disease (GD) and in most cases decrease during treatment. Its relation to Graves’ orbitopathy (GO) has not been clarified. Previously, a risk of GO has been linked to smoking, TSH receptor stimulation, high TSH-receptor antibodies (TRAb), low thyroid peroxidase and thyroglobulin antibodies (TPOAb, TgAb). METHODS: We examined Tg levels in 30 consecutive patients with GD were given drug therapy (methimazole + thyroxine) for up to 24 months. GO was identified by clinical signs and symptoms. 17 patients had GO, 11 of whom had it at diagnosis while 6 developed GO during treatment. During the study, 5 subjects were referred to radioiodine treatment, 3 to surgery. The remaining 22 subjects (GO n = 12, non-GO n = 10) completed the drug regimen. RESULTS: At diagnosis, Tg levels in GO patients (n = 11) were higher (84, 30–555 µg/L, median, range) than in non-GO patients (n = 19) (38, 3.5–287 µg/L), p = 0.042. Adding the 6 subjects who developed eye symptoms during treatment to the GO group (n = 17), yielded p = 0.001 vs. non-GO (n = 13). TRAb tended to be higher, while TPOAb and TgAb tended to be lower in the GO group. For the 22 patients who completed the drug regimen, Tg levels were higher in GO (n = 12) vs. non-GO (n = 10), p = 0.004, whereas TRAb levels did not differ. CONCLUSION: The data may suggest that evaluation of thyroglobulin levels in GD could contribute to identify patients at increased risk of developing GO. Possibly, thyroidal release of Tg in GD reflects a disturbance that also impacts retroorbital tissues. Springer International Publishing 2021-01-29 2021 /pmc/articles/PMC8357771/ /pubmed/33515213 http://dx.doi.org/10.1007/s40618-021-01505-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Khamisi, S.
Lundqvist, M.
Emadi, P.
Almby, K.
Ljunggren, Ö.
Karlsson, F. A.
Serum thyroglobulin is associated with orbitopathy in Graves’ disease
title Serum thyroglobulin is associated with orbitopathy in Graves’ disease
title_full Serum thyroglobulin is associated with orbitopathy in Graves’ disease
title_fullStr Serum thyroglobulin is associated with orbitopathy in Graves’ disease
title_full_unstemmed Serum thyroglobulin is associated with orbitopathy in Graves’ disease
title_short Serum thyroglobulin is associated with orbitopathy in Graves’ disease
title_sort serum thyroglobulin is associated with orbitopathy in graves’ disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357771/
https://www.ncbi.nlm.nih.gov/pubmed/33515213
http://dx.doi.org/10.1007/s40618-021-01505-8
work_keys_str_mv AT khamisis serumthyroglobulinisassociatedwithorbitopathyingravesdisease
AT lundqvistm serumthyroglobulinisassociatedwithorbitopathyingravesdisease
AT emadip serumthyroglobulinisassociatedwithorbitopathyingravesdisease
AT almbyk serumthyroglobulinisassociatedwithorbitopathyingravesdisease
AT ljunggreno serumthyroglobulinisassociatedwithorbitopathyingravesdisease
AT karlssonfa serumthyroglobulinisassociatedwithorbitopathyingravesdisease